Dynavax Technologies (NASDAQ:DVAX) Research Coverage Started at HC Wainwright

HC Wainwright initiated coverage on shares of Dynavax Technologies (NASDAQ:DVAX) in a report released on Friday morning, BenzingaRatingsTable reports. The firm issued a buy rating and a $13.00 target price on the biopharmaceutical company’s stock.

A number of other equities research analysts also recently issued reports on DVAX. Zacks Investment Research downgraded shares of Dynavax Technologies from a buy rating to a hold rating in a research note on Tuesday, October 15th. William Blair reiterated a buy rating on shares of Dynavax Technologies in a report on Friday, August 16th. BidaskClub lowered shares of Dynavax Technologies from a buy rating to a hold rating in a report on Friday, August 30th. Cantor Fitzgerald upgraded shares of Dynavax Technologies from a neutral rating to an overweight rating and set a $20.00 price objective for the company in a report on Wednesday, July 10th. Finally, ValuEngine upgraded shares of Dynavax Technologies from a sell rating to a hold rating in a report on Thursday, August 1st. Three analysts have rated the stock with a hold rating and five have issued a buy rating to the company. The company currently has a consensus rating of Buy and an average target price of $16.10.

DVAX stock opened at $4.08 on Friday. The company has a market capitalization of $276.26 million, a PE ratio of -1.60 and a beta of 0.46. The company has a debt-to-equity ratio of 19.95, a quick ratio of 3.47 and a current ratio of 4.30. Dynavax Technologies has a 52 week low of $2.60 and a 52 week high of $13.75. The company’s 50-day simple moving average is $4.15 and its 200 day simple moving average is $4.75.

Dynavax Technologies (NASDAQ:DVAX) last announced its quarterly earnings data on Wednesday, August 7th. The biopharmaceutical company reported ($0.66) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.63) by ($0.03). The firm had revenue of $8.30 million for the quarter, compared to analyst estimates of $8.24 million. Dynavax Technologies had a negative return on equity of 304.71% and a negative net margin of 781.10%. The company’s quarterly revenue was up 564.0% on a year-over-year basis. During the same quarter in the previous year, the company earned ($0.63) earnings per share. On average, analysts forecast that Dynavax Technologies will post -1.95 EPS for the current year.

In other Dynavax Technologies news, Director Francis Cano acquired 16,667 shares of the company’s stock in a transaction that occurred on Monday, August 12th. The stock was acquired at an average price of $3.00 per share, for a total transaction of $50,001.00. Following the acquisition, the director now directly owns 118,484 shares in the company, valued at $355,452. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 4.90% of the stock is owned by company insiders.

Large investors have recently added to or reduced their stakes in the business. M&T Bank Corp grew its position in shares of Dynavax Technologies by 29.5% during the 2nd quarter. M&T Bank Corp now owns 13,685 shares of the biopharmaceutical company’s stock worth $54,000 after buying an additional 3,116 shares during the period. Ladenburg Thalmann Financial Services Inc. grew its position in Dynavax Technologies by 95.0% in the 2nd quarter. Ladenburg Thalmann Financial Services Inc. now owns 6,984 shares of the biopharmaceutical company’s stock valued at $28,000 after purchasing an additional 3,402 shares during the period. Bank of Montreal Can grew its position in Dynavax Technologies by 148.4% in the 2nd quarter. Bank of Montreal Can now owns 7,440 shares of the biopharmaceutical company’s stock valued at $29,000 after purchasing an additional 4,445 shares during the period. Swiss National Bank grew its position in Dynavax Technologies by 4.2% in the 2nd quarter. Swiss National Bank now owns 119,078 shares of the biopharmaceutical company’s stock valued at $475,000 after purchasing an additional 4,800 shares during the period. Finally, Wedbush Securities Inc. acquired a new stake in Dynavax Technologies in the 2nd quarter valued at $42,000. 80.84% of the stock is owned by institutional investors and hedge funds.

About Dynavax Technologies

Dynavax Technologies Corporation, a biopharmaceutical company, focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. The company markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in adults age 18 years and older.

Read More: Backdoor Roth IRA Conversion and Strategy

Analyst Recommendations for Dynavax Technologies (NASDAQ:DVAX)

Receive News & Ratings for Dynavax Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies and related companies with MarketBeat.com's FREE daily email newsletter.